stocks logo

KRYS

Krystal Biotech Inc
$
146.480
+2.86(1.991%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
146.480
Open
146.000
VWAP
145.94
Vol
13.54K
Mkt Cap
4.16B
Low
146.000
Amount
1.98M
EV/EBITDA(TTM)
21.98
Total Shares
28.56M
EV
3.47B
EV/OCF(TTM)
17.78
P/S(TTM)
11.94
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
93.72M
+11.79%
--
--
105.48M
+15.74%
--
--
130.00M
+47.42%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Krystal Biotech, Inc. (KRYS) for FY2025, with the revenue forecasts being adjusted by -4.34% over the past three months. During the same period, the stock price has changed by 8.88%.
Revenue Estimates for FY2025
Revise Downward
down Image
-4.34%
In Past 3 Month
Stock Price
Go Up
up Image
+8.88%
In Past 3 Month
11 Analyst Rating
up Image
31.55% Upside
Wall Street analysts forecast KRYS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRYS is 192.70 USD with a low forecast of 149.00 USD and a high forecast of 240.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
1 Hold
0 Sell
Strong Buy
up Image
31.55% Upside
Current: 146.480
sliders
Low
149.00
Averages
192.70
High
240.00
Citi
Yigal Nochomovitz
Neutral
downgrade
$176 -> $166
2025-08-04
Reason
Citi analyst Yigal Nochomovitz lowered the firm's price target on Krystal Biotech to $166 from $176 and keeps a Neutral rating on the shares after its Q2 earnings miss. The company saw Vyjuvek sales up 9% q/q, though this was tempered by cautionary commentary referencing Q3 US Vyjuvek expected to fall "below Q2", the analyst tells investors in a research note. Citi adds however that launches in Europe and Japan are important upside levers for Krystal that could eventually earn a stock recommendation.
BofA
Alec Stranahan
Buy
downgrade
$192 -> $182
2025-08-04
Reason
BofA analyst Alec Stranahan lowered the firm's price target on Krystal Biotech to $182 from $192 and keeps a Buy rating on the shares. While there were some positives from the Q2 report, the firm expects investors will be concerned about the near-term growth trajectory given management expects Q3 revenue to be below Q2 based on patient pausing trends. Following the quarterly report, the firm updated its model to reflect decreased near-term Vyjuvek revenues and pushed back launches for KB407 and KB408.
BofA
Buy
downgrade
$193 -> $192
2025-07-22
Reason
BofA lowered the firm's price target on Krystal Biotech to $192 from $193 and keeps a Buy rating on the shares. The firm, which continues to see growth potential for Vyjuvek with launches outside of the U.S. this year, updated its model and slightly lowered near-term Vyjuvek revenues while increasing SG&A costs to reflect hiring of additional sales reps.
Citi
Neutral
maintain
$155 -> $176
2025-07-09
Reason
Citi raised the firm's price target on Krystal Biotech to $176 from $155 and keeps a Neutral rating on the shares. KB801 is an underappreciated asset that may be able to show differentiation from commercial Oxervate given its 's better dosing regimen and potentially superior NGF protein duration, and the firm has incorporated the KB801 program into its model, assigning it a 25% probability of success, the analyst tells investors in a research note.
Clear Street
Bill Maughan
Buy
initiated
$190
2025-06-30
Reason
Clear Street analyst Bill Maughan initiated coverage of Krystal Biotech with a Buy rating and $190 price target. Krystal's first commercial product, Vyjuvek for the treatment of dystrophic epidermolysis bullosa, is now nearly two years into launch and the company is developing and marketing therapies from its herpes simplex virus-platform-derived pipeline of gene therapies, notes the analyst. The post Q1 pullback in the stock was "overdone" and current trading levels reflect "expectations below the likely range of possibilities for the foreseeable future," says the analyst, who adds that Krystal has several pipeline programs that "would add to the valuation with any success."
Citi
Neutral
downgrade
$215 -> $155
2025-05-16
Reason
Citi lowered the firm's price target on Krystal Biotech to $155 from $215 and keeps a Neutral rating on the shares. The company's Q1 report reinforced moderating U.S. Vyjuvek dynamics, the analyst tells investors in a research note. Citi lowered its peak U.S. Vyjuvek to $500M from $700M and peak global Vyjuvek sales estimate to $700M from $1B. The firm says that despite the share pullback, a Neutral rating remains appropriate on Krystal Biotech.

Valuation Metrics

The current forward P/E ratio for Krystal Biotech Inc (KRYS.O) is 22.24, compared to its 5-year average forward P/E of -18.15. For a more detailed relative valuation and DCF analysis to assess Krystal Biotech Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-18.15
Current PE
22.24
Overvalued PE
47.82
Undervalued PE
-84.12

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
10.24
Current EV/EBITDA
17.08
Overvalued EV/EBITDA
57.15
Undervalued EV/EBITDA
-36.67

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
163.97
Current PS
8.43
Overvalued PS
743.77
Undervalued PS
-415.83

Financials

Annual
Quarterly
FY2025Q2
YoY :
+36.65%
96.04M
Total Revenue
FY2025Q2
YoY :
+86.59%
39.31M
Operating Profit
FY2025Q2
YoY :
+146.23%
38.33M
Net Income after Tax
FY2025Q2
YoY :
+143.40%
1.29
EPS - Diluted
FY2025Q2
YoY :
-1059.14%
50.83M
Free Cash Flow
FY2025Q2
YoY :
+1.19%
92.54
Gross Profit Margin - %
FY2025Q2
51.63
FCF Margin - %
FY2025Q2
YoY :
+80.18%
39.91
Net Margin - %
FY2025Q2
15.61
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
15.0M
USD
20
3-6
Months
17.8M
USD
4
6-9
Months
16.6M
USD
5
0-12
Months
19.8M
USD
4
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
115.5K
Volume
2
6-9
Months
257.1K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
3
385.8K
Volume
Months
6-9
4
234.8K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

KRYS News & Events

Events Timeline

2025-08-04 (ET)
2025-08-04
11:03:34
Video: Why These Stocks Are Moving Today
select
link
2025-08-04
07:02:37
Krystal Biotech reports Q2 EPS $1.29, consensus $1.44
select
2025-07-25 (ET)
2025-07-25
09:04:00
Krystal Biotech announces approval of VYJUVEK by Japan's MHLW
select
Sign Up For More Events

News

4.0
08-05Benzinga
Citigroup Maintains Neutral on Krystal Biotech, Lowers Price Target to $166
6.5
08-05NASDAQ.COM
Analysts Expect IJR Will Reach $131
4.5
08-04Benzinga
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results
Sign Up For More News

FAQ

arrow icon

What is Krystal Biotech Inc (KRYS) stock price today?

The current price of KRYS is 146.48 USD — it has increased 1.99 % in the last trading day.

arrow icon

What is Krystal Biotech Inc (KRYS)'s business?

arrow icon

What is the price predicton of KRYS Stock?

arrow icon

What is Krystal Biotech Inc (KRYS)'s revenue for the last quarter?

arrow icon

What is Krystal Biotech Inc (KRYS)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Krystal Biotech Inc (KRYS)'s fundamentals?

arrow icon

How many employees does Krystal Biotech Inc (KRYS). have?

arrow icon

What is Krystal Biotech Inc (KRYS) market cap?